Clinical trials · Boston, MA
Pancreatic Ductal Adenocarcinoma clinical trials in Boston
We’re tracking 35 recruiting pancreatic ductal adenocarcinoma studies with a site in or near Boston — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Boston, MassachusettsAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Boston, MassachusettsAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Boston, MassachusettsAges 18 years+ - NCT07217717RecruitingPhase 3
New PET scan for pancreatic cancer staging
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
Boston, MassachusettsAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Boston, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Boston, MassachusettsAges 18 years+ - NCT07024615RecruitingPhase 1
Study of ASP2138 before surgery for pancreatic cancer
This study tests an experimental drug, ASP2138, given before surgery for pancreatic cancer that is still removable. After surgery, you will receive standard chemotherapy. The goal is to see if adding ASP2138 before surgery helps improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07047807Recruiting
Digital support app for pancreatic cancer patients starting treatment
This trial tests a smartphone app designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy before surgery. The app aims to help you manage your care and feel more supported during this time.
Boston, MassachusettsAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Boston, MassachusettsAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT05968326RecruitingPhase 2
Chemo plus new vaccines versus chemo alone after pancreatic surgery
This Phase 2 trial tests whether adding two study medicines (an immune-based vaccine treatment plus atezolizumab) to standard chemo helps prevent pancreatic cancer from coming back after surgery. It compares the combination against standard chemo alone, looking at safety and how well it prevents relapse.
Boston, MassachusettsAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Boston, MassachusettsAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Boston, MassachusettsAges 18–100 - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Boston, MassachusettsAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Boston, MassachusettsAges 18 years+ - NCT07252232RecruitingPhase 3
A pill to prevent pancreatic cancer recurrence after surgery
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
Boston, MassachusettsAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Boston, MassachusettsAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Boston, MassachusettsAges 1–30 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Boston, MassachusettsAges 18 years+ - NCT06122896RecruitingEarly Phase 1
Screening for pancreatic cancer in high-risk people
This trial uses MRI and endoscopic ultrasound to look for early signs of pancreatic cancer in people who have a high risk due to their genes or family history. Finding it early may lead to better treatment options.
Boston, MassachusettsAges 18 years+ - NCT04970056Recruiting
Pancreatic cancer risk and early-detection registry study
This study builds a database of people at higher risk for pancreatic cancer (or certain early warning findings) to help find better ways to detect the disease early. You may be asked to complete health questionnaires and possibly donate a blood/saliva/swab sample.
Boston, MassachusettsAges 18–90
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Pancreatic Ductal Adenocarcinoma trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting pancreatic ductal adenocarcinoma studies listed above.
- Massachusetts General Hospital · 13 studies
- Dana-Farber Cancer Institute · 10 studies
- Brigham and Women's Hospital · 2 studies
- Research Site · 2 studies
- Beth Israel Deaconess Medical Center
- Boston Medical Center
- Brown University
- Investigative Site
What taking part in a pancreatic ductal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting pancreatic ductal adenocarcinoma studies in Massachusetts.
Common questions
- Are there pancreatic ductal adenocarcinoma clinical trials near Boston?
- Yes. We're currently tracking 35 recruiting pancreatic ductal adenocarcinoma studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic ductal adenocarcinoma study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic ductal adenocarcinoma studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.